Mullard, A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 20, 491–495 (2021).
Google Scholar
Rawat, P. et al. YAbS: The Antibody Society’s antibody therapeutics database. mAbs 17, 2468845 (2025).
Google Scholar
Chan, A. C., Martyn, G. D. & Carter, P. J. Fifty years of monoclonals: the past, present and future of antibody therapeutics. Nat. Rev. Immunol. 25, 745–765 (2025).
Google Scholar
Sathish, J. G. et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat. Rev. Drug Discov. 12, 306–324 (2013).
Google Scholar
Wilkinson, I. & Hale, G. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. mAbs 14, 2123299 (2022).
Google Scholar
Keri, D., Walker, M., Singh, I., Nishikawa, K. & Garces, F. Next generation of multispecific antibody engineering. Antib. Ther. 7, 37–52 (2024).
Google Scholar
Bates, A. & Power, C. A. David vs. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies 8, 28 (2019).
Google Scholar
Albayrak, G., Wan, P. K., Fisher, K. & Seymour, L. W. T cell engagers: expanding horizons in oncology and beyond. Br. J. Cancer 133, 1241–1249 (2025).
Google Scholar
Zhu, W. M. & Middleton, M. R. Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. Immunother. Adv. 3, ltad013 (2023).
Google Scholar
Van Wauwe, J. P., De Mey, J. R. & Goossens, J. G. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J. Immunol. 124, 2708–2713 (1980).
Google Scholar
Jhajj, H. S., Lwo, T. S., Yao, E. L. & Tessier, P. M. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. Trends Mol. Med. 29, 48–60 (2023).
Google Scholar
Lim, S. H., Beers, S. A., Al-Shamkhani, A. & Cragg, M. S. Agonist antibodies for cancer immunotherapy: history, hopes, and challenges. Clin. Cancer Res. 30, 1712–1723 (2024).
Google Scholar
Mayes, P. A., Hance, K. W. & Hoos, A. The promise and challenges of immune agonist antibody development in cancer. Nat. Rev. Drug Discov. 17, 509–527 (2018).
Google Scholar
Paluch, C., Santos, A. M., Anzilotti, C., Cornall, R. J. & Davis, S. J. Immune checkpoints as therapeutic targets in autoimmunity. Front. Immunol. 9, 2306 (2018).
Google Scholar
Fromm, G., de Silva, S. & Schreiber, T. H. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. Front. Immunol. 14, 1236332 (2023).
Google Scholar
Sedger, L. M. & McDermott, M. F. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants — past, present and future. Cytokine Growth Factor Rev. 25, 453–472 (2014).
Google Scholar
Saxton, R. A., Glassman, C. R. & Garcia, K. C. Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov. 22, 21–37 (2023).
Google Scholar
Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414–1430.e19 (2022).
Google Scholar
Pekar, L., Krah, S. & Zielonka, S. Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics. Expert Opin. Biol. Ther. 24, 115–118 (2024).
Google Scholar
Lovewell, R. R., Langermann, S. & Flies, D. B. Immune inhibitory receptor agonist therapeutics. Front. Immunol. 16, 1566869 (2025).
Google Scholar
Dushek, O., Goyette, J. & van der Merwe, P. A. Non-catalytic tyrosine-phosphorylated receptors. Immunol. Rev. 250, 258–276 (2012).
Google Scholar
Bucktrout, S. L., Bluestone, J. A. & Ramsdell, F. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Med. 10, 79 (2018).
Google Scholar
Thiel, K. W. & Giangrande, P. H. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 19, 209–222 (2009).
Google Scholar
Zhou, G. et al. Aptamers: a promising chemical antibody for cancer therapy. Oncotarget 7, 13446–13463 (2016).
Google Scholar
Lu, H., Cheng, Z., Hu, Y. & Tang, L. V. What can de novo protein design bring to the treatment of hematological disorders? Biology 12, 166 (2023).
Google Scholar
Adams, C. S. et al. De novo design of protein minibinder agonists of TLR3. Nat. Commun. 16, 1234 (2025).
Google Scholar
Fontaine, T. et al. Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist. Nat. Commun. 15, 7029 (2024).
Google Scholar
Dunn, M. E. et al. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature 633, 654–661 (2024).
Google Scholar
Dostert, C., Grusdat, M., Letellier, E. & Brenner, D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol. Rev. 99, 115–160 (2019).
Google Scholar
Hehlgans, T. & Pfeffer, K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115, 1–20 (2005).
Google Scholar
Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501 (2001).
Google Scholar
Vanamee, É. S. & Faustman, D. L. Structural principles of tumor necrosis factor superfamily signaling. Sci. Signal. 11, eaao4910 (2018).
Google Scholar
Holbrook, J., Lara-Reyna, S., Jarosz-Griffiths, H. & McDermott, M. Tumour necrosis factor signalling in health and disease. F1000Research https://doi.org/10.12688/f1000research.17023.1 (2019).
Wajant, H., Pfizenmaier, K. & Scheurich, P. Tumor necrosis factor signaling. Cell Death Differ. 10, 45–65 (2003).
Google Scholar
Xie, P. TRAF molecules in cell signaling and in human diseases. J. Mol. Signal. 8, 7 (2013).
Google Scholar
Elgueta, R. et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152–172 (2009).
Google Scholar
Hendriks, J. et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1, 433–440 (2000).
Google Scholar
Chester, C., Sanmamed, M. F., Wang, J. & Melero, I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood 131, 49–57 (2018).
Google Scholar
Croft, M., So, T., Duan, W. & Soroosh, P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol. Rev. 229, 173–191 (2009).
Google Scholar
Hsu, H., Xiong, J. & Goeddel, D. V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81, 495–504 (1995).
Google Scholar
Peter, M. E. et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22, 549–559 (2015).
Google Scholar
Ashkenazi, A. & Herbst, R. S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Investig. 118, 1979–1990 (2008).
Google Scholar
Suo, F., Zhou, X., Setroikromo, R. & Quax, W. J. Receptor specificity engineering of TNF superfamily ligands. Pharmaceutics https://doi.org/10.3390/pharmaceutics14010181 (2022).
Bremer, E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. Int. Sch. Res. Notices Oncol. 2013, 371854 (2013).
Wajant, H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ. 22, 1727–1741 (2015).
Google Scholar
Kucka, K. & Wajant, H. Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily. Front. Cell Dev. Biol. 8, 615141 (2020).
Google Scholar
Naismith, J. H., Devine, T. Q., Brandhuber, B. J. & Sprang, S. R. Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J. Biol. Chem. 270, 13303–13307 (1995).
Google Scholar
Siegel, R. M. et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288, 2354–2357 (2000).
Google Scholar
Chan, F. K. et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351–2354 (2000).
Google Scholar
Smulski, C. R. et al. Cysteine-rich domain 1 of CD40 mediates receptor self-assembly. J. Biol. Chem. 288, 10914–10922 (2013).
Google Scholar
Papoff, G. et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J. Biol. Chem. 274, 38241–38250 (1999).
Google Scholar
Neumann, S., Hasenauer, J., Pollak, N. & Scheurich, P. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J. Biol. Chem. 289, 16576–16587 (2014).
Google Scholar
Cao, J., Meng, F., Gao, X., Dong, H. & Yao, W. Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination. Protein J. 30, 281–289 (2011).
Google Scholar
Karathanasis, C. et al. Single-molecule imaging reveals the oligomeric state of functional TNFα-induced plasma membrane TNFR1 clusters in cells. Sci. Signal. 13, eaax5647 (2020).
Google Scholar
Bartels, N. et al. Advanced multiparametric image spectroscopy and super-resolution microscopy reveal a minimal model of CD95 signal initiation. Sci. Adv. 10, eadn3238 (2024).
Google Scholar
Kanazawa, K. & Kudo, A. Self-assembled RANK induces osteoclastogenesis ligand-independently. J. Bone Miner. Res. 20, 2053–2060 (2005).
Google Scholar
Brown, S. A. N., Cheng, E., Williams, M. S. & Winkles, J. A. TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PLoS ONE 8, e65248 (2013).
Google Scholar
Chin, S. M. et al. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nat. Commun. 9, 4679 (2018).
Google Scholar
Liu, W. et al. Mechanistic basis for functional promiscuity in the TNF and TNF receptor superfamilies: structure of the LIGHT:DcR3 assembly. Structure 22, 1252–1262 (2014).
Google Scholar
Liu, W. et al. Crystal structure of the complex of human FasL and its decoy receptor DcR3. Structure 24, 2016–2023 (2016).
Google Scholar
Zhan, C. et al. Decoy strategies: the structure of TL1A:DcR3 complex. Structure 19, 162–171 (2011).
Google Scholar
Mukai, Y. et al. Solution of the structure of the TNF-TNFR2 complex. Sci. Signal. 3, ra83 (2010).
Google Scholar
Banner, D. W. et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell 73, 431–445 (1993).
Google Scholar
Compaan, D. M. & Hymowitz, S. G. The crystal structure of the costimulatory OX40-OX40L complex. Structure 14, 1321–1330 (2006).
Google Scholar
McMillan, D. et al. Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF. Nat. Commun. 12, 582 (2021).
Google Scholar
Saitoh, T. et al. TWEAK induces NF-κB2 p100 processing and long lasting NF-κB activation. J. Biol. Chem. 278, 36005–36012 (2003).
Google Scholar
Varfolomeev, E. et al. Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by members of the TNF family of receptors. Sci. Signal. 5, ra22 (2012).
Google Scholar
Dueber, E. C. et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334, 376–380 (2011).
Google Scholar
Mace, P. D., Smits, C., Vaux, D. L., Silke, J. & Day, C. L. Asymmetric recruitment of cIAPs by TRAF2. J. Mol. Biol. 400, 8–15 (2010).
Google Scholar
Park, Y. C., Burkitt, V., Villa, A. R., Tong, L. & Wu, H. Structural basis for self-association and receptor recognition of human TRAF2. Nature 398, 533–538 (1999).
Google Scholar
Zheng, C., Kabaleeswaran, V., Wang, Y., Cheng, G. & Wu, H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol. Cell 38, 101–113 (2010).
Google Scholar
Feltham, R. et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J. Biol. Chem. 286, 17015–17028 (2011).
Google Scholar
Esposito, D. et al. Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95 C terminus. Structure 18, 1378–1390 (2010).
Google Scholar
Dickens, L. S. et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol. Cell 47, 291–305 (2012).
Google Scholar
Scott, F. L. et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 457, 1019–1022 (2009).
Google Scholar
Schleich, K. et al. Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol. Cell 47, 306–319 (2012).
Google Scholar
Wang, L. et al. The Fas–FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat. Struct. Mol. Biol. 17, 1324–1329 (2010).
Google Scholar
Fosuah, E. et al. Assembly and activation of the death-inducing signaling complex. Proc. Natl Acad. Sci. USA 122, e2504819122 (2025).
Google Scholar
Lim, C. S., Lee, J., Kim, J. W. & Lee, J. O. Highly ordered clustering of TNFα and BAFF ligand-receptor-intracellular adaptor complexes on a lipid membrane. Nat. Commun. 16, 5551 (2025).
Google Scholar
Kuester, M., Kemmerzehl, S., Dahms, S. O., Roeser, D. & Than, M. E. The crystal structure of death receptor 6 (DR6): a potential receptor of the amyloid precursor protein (APP). J. Mol. Biol. 409, 189–201 (2011).
Google Scholar
Liu, C. et al. Structural and functional insights of RANKL–RANK interaction and signaling. J. Immunol. 184, 6910–6919 (2010).
Google Scholar
Yu, X. et al. Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. Cancer Cell 33, 664–675.e4 (2018).
Google Scholar
Heckel, F. et al. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Commun. Biol. 5, 229 (2022).
Google Scholar
Bartkowiak, T. et al. Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway. Clin. Cancer Res. 24, 1138–1151 (2018).
Google Scholar
Eskiocak, U. et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight 5, e133647 (2020).
Google Scholar
Griffiths, J. et al. Domain binding and isotype dictate the activity of anti-human OX40 antibodies. J. ImmunoTher. Cancer 8, e001557 (2020).
Google Scholar
Leonard, B. et al. Antibody homotypic interactions are encoded by germline light chain complementarity determining region 2. Proc. Natl Acad. Sci. USA 119, e2201562119 (2022).
Google Scholar
Romei, M. G. et al. i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists. Nat. Commun. 15, 642 (2024).
Google Scholar
Chodorge, M. et al. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ. 19, 1187–1195 (2012).
Google Scholar
Wang, R. et al. An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors. Clin. Cancer Res. 25, 6709–6720 (2019).
Google Scholar
Ho, S. K. et al. Epitope and Fc-mediated cross-linking, but not high affinity, are critical for antitumor activity of CD137 agonist antibody with reduced liver toxicity. Mol. Cancer Ther. 19, 1040–1051 (2020).
Google Scholar
Yu, X. et al. Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature 614, 539–547 (2023).
Google Scholar
Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).
Google Scholar
Beers, S. A., Glennie, M. J. & White, A. L. Influence of immunoglobulin isotype on therapeutic antibody function. Blood 127, 1097–1101 (2016).
Google Scholar
White, A. L. et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754–1763 (2011).
Google Scholar
Li, F. & Ravetch, J. V. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030–1034 (2011).
Google Scholar
Dahan, R. et al. Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagement. Cancer Cell 29, 820–831 (2016).
Google Scholar
White, A. L. et al. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. J. Immunol. 193, 1828–1835 (2014).
Google Scholar
Yu, X. et al. TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity. Commun. Biol. 4, 772 (2021).
Google Scholar
White, A. L. et al. FcγRIIB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol. Immunother. 62, 941–948 (2013).
Google Scholar
Li, F. & Ravetch, J. V. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc. Natl Acad. Sci. USA 110, 19501–19506 (2013).
Google Scholar
White, A. L. et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 27, 138–148 (2015).
Google Scholar
Nimmerjahn, F., Vidarsson, G. & Cragg, M. S. Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy. Nat. Immunol. 24, 1244–1255 (2023).
Google Scholar
Liu, X. et al. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nat. Commun. 10, 4206 (2019).
Google Scholar
Orr, C. M. et al. Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Sci. Immunol. 7, eabm3723 (2022).
Google Scholar
Elliott, I. G. et al. Structure-guided disulfide engineering restricts antibody conformation to elicit TNFR agonism. Nat. Commun. 16, 3495 (2025).
Google Scholar
Davis, S. J. & van der Merwe, P. A. The kinetic-segregation model: TCR triggering and beyond. Nat. Immunol. 7, 803–809 (2006).
Google Scholar
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
Google Scholar
Iwai, Y., Hamanishi, J., Chamoto, K. & Honjo, T. Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci. 24, 26 (2017).
Google Scholar
Kung, P., Goldstein, G., Reinherz, E. L. & Schlossman, S. F. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206, 347–349 (1979).
Google Scholar
Chatenoud, L., Herold, K. C., Bach, J. F. & Bluestone, J. A. The teplizumab saga: the challenge of not getting lost in clinical translation. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a041600 (2024).
Google Scholar
Gaglia, J. & Kissler, S. Anti-CD3 antibody for the prevention of type 1 diabetes: a story of perseverance. Biochemistry 58, 4107–4111 (2019).
Google Scholar
Borst, J., Prendiville, M. A. & Terhorst, C. Complexity of the human T lymphocyte-specific cell surface antigen T3. J. Immunol. 128, 1560–1565 (1982).
Google Scholar
Borst, J., Alexander, S., Elder, J. & Terhorst, C. The T3 complex on human T lymphocytes involves four structurally distinct glycoproteins. J. Biol. Chem. 258, 5135–5141 (1983).
Google Scholar
Cosimi, A. B. et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32, 535–540 (1981).
Google Scholar
Cosimi, A. B. et al. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 43, 91–95 (1987).
Google Scholar
Fung, J. J. et al. Use of OKT3 with ciclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron 46, 19–33 (1987).
Google Scholar
Gilbert, E. M. et al. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am. J. Med. 82, 202–206 (1987).
Google Scholar
Prentice, H. G. et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 319, 700–703 (1982).
Google Scholar
Leo, O., Foo, M., Sachs, D. H., Samelson, L. E. & Bluestone, J. A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl Acad. Sci. USA 84, 1374–1378 (1987).
Google Scholar
Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002).
Google Scholar
Alkemade, G. M. et al. Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. Diabetes/Metab. Res. Rev. 27, 925–927 (2011).
Google Scholar
Abbs, I. C. et al. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Ther. Immunol. 1, 325–331 (1994).
Google Scholar
Smith, J. A., Tso, J. Y., Clark, M. R., Cole, M. S. & Bluestone, J. A. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 185, 1413–1422 (1997).
Google Scholar
Penaranda, C., Tang, Q. & Bluestone, J. A. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J. Immunol. 187, 2015–2022 (2011).
Google Scholar
Lühder, F. et al. Topological requirements and signaling properties of T cell–activating, anti-CD28 antibody superagonists. J. Exp. Med. 197, 955–966 (2003).
Google Scholar
Tacke, M., Hanke, G., Hanke, T. & Hünig, T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27, 239–247 (1997).
Google Scholar
Evans, E. J. et al. Crystal structure of a soluble CD28-Fab complex. Nat. Immunol. 6, 271–279 (2005).
Google Scholar
Davies, D. R. & Cohen, G. H. Interactions of protein antigens with antibodies. Proc. Natl Acad. Sci. USA 93, 7–12 (1996).
Google Scholar
Davis, S. J. et al. Antibody and HIV-1 gp120 recognition of CD4 undermines the concept of mimicry between antibodies and receptors. Nature 358, 76–79 (1992).
Google Scholar
Davis, S. J. & van der Merwe, P. A. The structure and ligand interactions of CD2: implications for T-cell function. Immunol. Today 17, 177–187 (1996).
Google Scholar
van der Merwe, P. A., Davis, S. J., Shaw, A. S. & Dustin, M. L. Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. Semin. Immunol. 12, 5–21 (2000).
Google Scholar
Irles, C. et al. CD45 ectodomain controls interaction with GEMs and Lck activity for optimal TCR signaling. Nat. Immunol. 4, 189–197 (2003).
Google Scholar
Lin, J. & Weiss, A. The tyrosine phosphatase CD148 is excluded from the immunologic synapse and down-regulates prolonged T cell signaling. J. Cell Biol. 162, 673–682 (2003).
Google Scholar
Lippert, A. H. et al. Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases. Immunity 57, 256–270.e10 (2024).
Google Scholar
Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001).
Google Scholar
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. & Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl Acad. Sci. USA 98, 13866–13871 (2001).
Google Scholar
Xu, X. et al. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J. Cell Biol. 219, e201905085 (2020).
Google Scholar
Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765–772 (1996).
Google Scholar
Vibhakar, R., Juan, G., Traganos, F., Darzynkiewicz, Z. & Finger, L. R. Activation-induced expression of Human Programmed Death-1 gene in T-lymphocytes. Exp. Cell Res. 232, 25–28 (1997).
Google Scholar
Keir, M. E., Latchman, Y. E., Freeman, G. J. & Sharpe, A. H. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J. Immunol. 175, 7372–7379 (2005).
Google Scholar
Seko, Y., Yagita, H., Okumura, K., Azuma, M. & Nagai, R. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. Cardiovasc. Res. 75, 158–167 (2007).
Google Scholar
Helou, D. G. et al. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. Nat. Commun. 11, 3998 (2020).
Google Scholar
Grebinoski, S. & Vignali, D. A. A. Inhibitory receptor agonists: the future of autoimmune disease therapeutics? Curr. Opin. Immunol. 67, 1–9 (2020).
Google Scholar
Suzuki, K. et al. Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases. Sci. Immunol. 8, eadd4947 (2023).
Google Scholar
Feng, Y. et al. PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation – therapeutic implications for autoimmunity. J. Autoimmun. 149, 103339 (2024).
Google Scholar
Lin, C. H. & Hünig, T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur. J. Immunol. 33, 626–638 (2003).
Google Scholar
Beyersdorf, N. et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202, 445–455 (2005).
Google Scholar
Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018–1028 (2006).
Google Scholar
Duff, G. Expert group on phase one clinical trials: final report. The National Archives https://webarchive.nationalarchives.gov.uk/ukgwa/20130105090249/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063117 (2006).
Horvath, C. et al. Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nat. Rev. Immunol. 12, 740 (2012).
Google Scholar
Hünig, T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat. Rev. Immunol. 12, 317–318 (2012).
Google Scholar
Eastwood, D. et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161, 512–526 (2010).
Google Scholar
Stebbings, R. et al. “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179, 3325–3331 (2007).
Google Scholar
Romer, P. S. et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 118, 6772–6782 (2011).
Google Scholar
Hussain, K. et al. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood 125, 102–110 (2015).
Google Scholar
Chenoweth, A. M. et al. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity. Immunol. Cell Biol. 101, 657–662 (2023).
Google Scholar
Milton, M. N. & Horvath, C. J. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development. Toxicol. Pathol. 37, 363–371 (2009).
Google Scholar
Tabares, P. et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur. J. Immunol. 44, 1225–1236 (2014).
Google Scholar
Leonard, W. J., Lin, J. X. & O’Shea, J. J. The γc family of cytokines: basic biology to therapeutic ramifications. Immunity 50, 832–850 (2019).
Google Scholar
Dougan, M., Dranoff, G. & Dougan, S. K. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity 50, 796–811 (2019).
Google Scholar
McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429–442 (2007).
Google Scholar
Conlon, K. C., Miljkovic, M. D. & Waldmann, T. A. Cytokines in the treatment of cancer. J. Interferon Cytokine Res. 39, 6–21 (2019).
Google Scholar
Feldmann, M. Many cytokines are very useful therapeutic targets in disease. J. Clin. Investig. 118, 3533–3536 (2008).
Google Scholar
Schreiber, G. & Walter, M. R. Cytokine–receptor interactions as drug targets. Curr. Opin. Chem. Biol. 14, 511–519 (2010).
Google Scholar
Takeuchi, T. Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases — RA as a role model. Inflamm. Regen. 42, 35 (2022).
Google Scholar
Schwartz, D. M., Bonelli, M., Gadina, M. & O’Shea, J. J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat. Rev. Rheumatol. 12, 25–36 (2016).
Google Scholar
Gadina, M. et al. Signaling by type I and II cytokine receptors: ten years after. Curr. Opin. Immunol. 13, 363–373 (2001).
Google Scholar
Wilmes, S. et al. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. Science 367, 643–652 (2020).
Google Scholar
Zhou, Y. et al. Structural insights into the assembly of gp130 family cytokine signaling complexes. Sci. Adv. 9, eade4395 (2023).
Google Scholar
Zanin, N., Viaris de Lesegno, C., Lamaze, C. & Blouin, C. M. Interferon receptor trafficking and signaling: journey to the cross roads. Front. Immunol. 11, 615603 (2020).
Google Scholar
Ouyang, W. & O’Garra, A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 50, 871–891 (2019).
Google Scholar
Atanasova, M. & Whitty, A. Understanding cytokine and growth factor receptor activation mechanisms. Crit. Rev. Biochem. Mol. Biol. 47, 502–530 (2012).
Google Scholar
Lim, A. C. et al. A diversity of antibody epitopes can induce signaling through the erythropoietin receptor. Biochemistry 49, 3797–3804 (2010).
Google Scholar
Zhang, H. et al. Selecting agonists from single cells infected with combinatorial antibody libraries. Cell Chem. Biol. 20, 734–741 (2013).
Google Scholar
Fuh, G. et al. Rational design of potent antagonists to the human growth hormone receptor. Science 256, 1677–1680 (1992).
Google Scholar
Moraga, I. et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell 160, 1196–1208 (2015).
Google Scholar
Mohan, K. et al. Topological control of cytokine receptor signaling induces differential effects in hematopoiesis. Science 364, eaav7532 (2019).
Google Scholar
Lipinski, B. et al. Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition. mAbs 15, 2236265 (2023).
Google Scholar
Saxton, R. A. et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science 371, eabc8433 (2021).
Google Scholar
Harris, K. E. et al. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Sci. Rep. 11, 10592 (2021).
Google Scholar
Kuruganti, S. et al. Cytokine activation by antibody fragments targeted to cytokine-receptor signaling complexes. J. Biol. Chem. 291, 447–461 (2016).
Google Scholar
Spangler, J. B., Moraga, I., Jude, K. M., Savvides, C. S. & Garcia, K. C. A strategy for the selection of monovalent antibodies that span protein dimer interfaces. J. Biol. Chem. 294, 13876–13886 (2019).
Google Scholar
Irie-Sasaki, J. et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349–354 (2001).
Google Scholar
Kojima, R., Scheller, L. & Fussenegger, M. Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation. Nat. Chem. Biol. 14, 42–49 (2018).
Google Scholar
Holder, P. G. et al. Engineering interferons and interleukins for cancer immunotherapy. Adv. Drug Deliv. Rev. 182, 114112 (2022).
Google Scholar
Lykhopiy, V., Malviya, V., Humblet-Baron, S. & Schlenner, S. M. IL-2 immunotherapy for targeting regulatory T cells in autoimmunity. Genes Immun. 24, 248–262 (2023).
Google Scholar
Klein, C., Brinkmann, U., Reichert, J. M. & Kontermann, R. E. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov. 23, 301–319 (2024).
Google Scholar
Yin, N. et al. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduct. Target. Ther. 9, 126 (2024).
Google Scholar
Johnson, P. et al. Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin. Cancer Res. 21, 1321–1328 (2015).
Google Scholar
Advani, R. et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J. Clin. Oncol. 27, 4371–4377 (2009).
Google Scholar
Garris, C. S., Wong, J. L., Ravetch, J. V. & Knorr, D. A. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Sci. Transl. Med. 13, eabd1346 (2021).
Google Scholar
Knorr, D. A., Dahan, R. & Ravetch, J. V. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc. Natl Acad. Sci. USA 115, 11048–11053 (2018).
Google Scholar
Osorio, J. C. et al. Abstract CT203: Fc-optimized anti-CD40 agonist antibody 2141-V11 for BCG-unresponsive non-muscle invasive bladder cancer: updates on phase 1 study clinical outcomes and biological correlatives. Cancer Res. 85, CT203 (2025).
Google Scholar
Mimoto, F. et al. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131. Protein Eng. Des. Sel. 26, 589–598 (2013).
Google Scholar
Osorio, J. C. et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell https://doi.org/10.1016/j.ccell.2025.07.013 (2025).
Google Scholar
Postel-Vinay, S. et al. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J. Immunother. Cancer 11, e005301 (2023).
Google Scholar
Gutierrez, M. et al. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors. Clin. Cancer Res. 27, 460–472 (2021).
Google Scholar
Willoughby, J. E. et al. Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations. J. Immunother. Cancer 12, e008677 (2024).
Google Scholar
Holay, N. et al. INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering. J. Immunother. Cancer 13, e011524 (2025).
Google Scholar
Segal, N. H. et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin. Cancer Res. 23, 1929–1936 (2017).
Google Scholar
Segal, N. H. et al. Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin. Cancer Res. 24, 1816–1823 (2018).
Google Scholar
Claus, C. et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci. Transl. Med. 11, eaav5989 (2019).
Google Scholar
Philipson, B. I. et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Sci. Signal. 13, eaay8248 (2020).
Google Scholar
Ma, Y. et al. Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin’s lymphoma. Cell Rep. Med. 5, 101414 (2024).
Google Scholar
Qi, X. et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat. Commun. 10, 2141 (2019).
Google Scholar
Ritchie, D. & Colonna, M. Mechanisms of action and clinical development of elotuzumab. Clin. Transl. Sci. 11, 261–266 (2018).
Google Scholar
Metzger, T. C. et al. ICOS promotes the function of CD4+ effector T cells during anti-OX40–mediated tumor rejection. Cancer Res. 76, 3684–3689 (2016).
Google Scholar
Sainson, R. C. A. et al. An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T-cell ratio and induces tumor regression. Cancer Immunol. Res. 8, 1568–1582 (2020).
Google Scholar
Hanson, A. et al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One 15, e0239595 (2020).
Google Scholar
Yadavilli, S. et al. Activating inducible T-cell costimulator yields antitumor activity alone and in combination with anti-PD-1 checkpoint blockade. Cancer Res. Commun. 3, 1564–1579 (2023).
Google Scholar
Gratuze, M., Leyns, C. E. G. & Holtzman, D. M. New insights into the role of TREM2 in Alzheimer’s disease. Mol. Neurodegener. 13, 66 (2018).
Google Scholar
Ma, Y. N. et al. The potential and challenges of TREM2-targeted therapy in Alzheimer’s disease: insights from the INVOKE-2 study. Front. Aging Neurosci. 17, 1576020 (2025).
Google Scholar
Vigil Neuroscience provides update on iluzanebart phase 2 IGNITE Trial in ALSP. Globe Newswire https://www.globenewswire.com/news-release/2025/06/04/3093434/0/en/Vigil-Neuroscience-Provides-Update-on-Iluzanebart-Phase-2-IGNITE-Trial-in-ALSP.html (2025).
Tuttle, J. et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N. Engl. J. Med. 388, 1853–1862 (2023).
Google Scholar
Tuttle J. et al. A phase 2b dose-ranging study of peresolimab for adults with RA. Arthritis Rheumatol. 77, abstr. 0473 (2025).
Simon, T. A. et al. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin. Arthritis Rheum. 64, 152240 (2024).
Google Scholar
Graf J, A. A. et al. Rosnilimab, a selective and potent depleter of pathogenic T cells, demonstrates efficacy, safety, and translational proof of mechanism in a rheumatoid arthritis phase 2B trial. Arthritis Rheumatol. 77, abstr. LB19 (2025).
Ling, I. T. C. et al. Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study. Ther. Adv. Musculoskelet. Dis. 17, 1759720X251385857 (2025).
Google Scholar
Brüggemann, M. et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351–1361 (1987).
Google Scholar
Cui, J. et al. Targeted depletion of PD-1-expressing cells induces immune tolerance through peripheral clonal deletion. Sci. Immunol. 9, eadh0085 (2024).
Google Scholar
Luu, K. et al. DOP81 Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: results from a phase 1 healthy volunteer clinical trial. J. Crohn’s Colitis 18, i225 (2024).
Google Scholar
Benschop, R. et al. Ab0502 Cellular and proteomic changes following administration of peresolimab, in a phase 2a trial in rheumatoid arthritis. Ann. Rheum. Dis. 83, 1521 (2024).
Google Scholar
Williams, E. L. et al. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J. Immunol. 191, 4130–4140 (2013).
Google Scholar
Ganesan, L. P. et al. FcγRIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol. 189, 4981–4988 (2012).
Google Scholar
Cheung, T. C. et al. Epitope topography of agonist antibodies to the checkpoint inhibitory receptor BTLA. Structure 31, 958–967.e3 (2023).
Google Scholar
Derebe, M. G., Nanjunda, R. K., Gilliland, G. L., Lacy, E. R. & Chiu, M. L. Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors. Immunol. Lett. 197, 1–8 (2018).
Google Scholar
Vesely, M. D., Lizzul, P. F., Klekotka, P., Joller, N. & Raff, A. Immune checkpoint agonists for inflammatory skin diseases. J. Investig. Dermatol. 145, 1268–1271 (2025).
Google Scholar
Koester, A. et al. Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study. Nat. Commun. 16, 4082 (2025).
Google Scholar
Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255–266 (2007).
Google Scholar
Läubli, H. & Varki, A. Disrupting Siglec-mediated interactions to develop immunotherapies for cancer treatment. Expert Opin. Ther. Targets 29, 613–619 (2025).
Google Scholar
Cambay, F. et al. Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors. Curr. Res. Immunol. 1, 23–37 (2020).
Google Scholar
Youngblood, B. A. et al. AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice. Int. Arch. Allergy Immunol. 180, 91–102 (2019).
Google Scholar
Dellon, E. S. et al. Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis. N. Engl. J. Med. 383, 1624–1634 (2020).
Google Scholar
Siebenhaar, F. et al. Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. Br. J. Dermatol. 189, 511–519 (2023).
Google Scholar
Schanin, J. et al. Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells. Commun. Biol. 5, 1226 (2022).
Google Scholar
Elieh-Ali-Komi, D. et al. Chronic urticaria and the pathogenic role of mast cells. Allergol. Int. 72, 359–368 (2023).
Google Scholar
Chen, G. Y., Tang, J., Zheng, P. & Liu, Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323, 1722–1725 (2009).
Google Scholar
Magenau, J. et al. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood 143, 21–31 (2024).
Google Scholar
Welker, J. et al. Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Infect. Dis. 22, 611–621 (2022).
Google Scholar
Merck to discontinue development of MK-7110 for COVID-19. Business Wire https://go.shr.lc/44I1erh (2021).
Liu, M. et al. CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. Signal Transduct. Target. Ther. 7, 224 (2022).
Google Scholar
Angin, M., Brignone, C. & Triebel, F. A LAG-3–specific agonist antibody for the treatment of T cell–induced autoimmune diseases. J. Immunol. 204, 810–818 (2020).
Google Scholar
Huang, C. C. et al. A novel apoptosis-inducing anti-PSGL-1 antibody for T cell-mediated diseases. Eur. J. Immunol. 35, 2239–2249 (2005).
Google Scholar
AltruBio presents new preclinical data at FOCIS 2025 demonstrating ALTB-268’s efficacy in T cell-mediated inflammatory models. Globe Newswire https://www.globenewswire.com/news-release/2025/06/23/3103244/0/en/AltruBio-Presents-New-Preclinical-Data-at-FOCIS-2025-Demonstrating-ALTB-268-s-Efficacy-in-T-Cell-Mediated-Inflammatory-Models.html (2025).
Lovewell, R. R. et al. LAIR-1 agonism as a therapy for acute myeloid leukemia. J. Clin. Investig. 133, e169519 (2023).
Google Scholar
Vitale, L. A. et al. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol. Immunother. 68, 233–245 (2019).
Google Scholar
Weiss, S. A. et al. A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on Anti-PD-1 therapy. Clin. Cancer Res. 30, 74–81 (2024).
Google Scholar
Filbert, E. L., Bjorck, P. K., Srivastava, M. K., Bahjat, F. R. & Yang, X. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunol. Immunother. 70, 1853–1865 (2021).
Google Scholar
Vonderheide, R. H. et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25, 876–883 (2007).
Google Scholar
O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021).
Google Scholar
Salomon, R. et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat. Cancer 3, 287–302 (2022).
Google Scholar
Fenis, A., Demaria, O., Gauthier, L., Vivier, E. & Narni-Mancinelli, E. New immune cell engagers for cancer immunotherapy. Nat. Rev. Immunol. 24, 471–486 (2024).
Google Scholar
Xu, Y. et al. FcγRs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 171, 562–568 (2003).
Google Scholar
Dhein, J. et al. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 149, 3166–3173 (1992).
Google Scholar
Sum, E. et al. Fibroblast activation protein α-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity. Clin. Cancer Res. 27, 4036–4053 (2021).
Google Scholar
Hesen, N. et al. Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism. Bioengineered 15, 2302246 (2024).
Google Scholar
